The emerging landscape of neo/adjuvant immunotherapy in renal cell carcinoma

Dibajnia, Pooya; Cardenas, Luisa; Lalani, Aly-Khan A.

doi:10.1080/21645515.2023.2178217

Cited by 15 publications

(17 citation statements)

References 80 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although combination therapies could enhance the objective response of the tumor compared with the use of single agents, the high toxic effects of the combined therapies could compromise the fitness of the patient to undergo surgery ( 3 ). Notably, radiographic overestimation of tumor size and the fibrotic changes induced by immunotherapy have an effect on the surgical decision-making process and intimate some difficulties with the operation ( 48 , 49 ). In addition, the combination therapies may become a challenge for the operating surgeon ( 50 ).…”

Section: Discussionmentioning

confidence: 99%

Effects of neoadjuvant VEGF‑TKI treatment on surgery for renal cell carcinoma: A systematic review and meta‑analysis

Zhu,

Liu,

Zhou

et al. 2024

Oncol Lett

View full text Add to dashboard Cite

To evaluate the effects of neoadjuvant vascular endothelial growth factor-tyrosine kinase inhibitor (VEGF-TKI) treatment on surgery in patients with renal cell carcinoma (RCC), sources from Embase, PubMed and the Cochrane Library databases collected from inception to December, 2022 were used for analysis in the present study, according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Data regarding surgical outcomes were collected. The pooled effect sizes were calculated in terms of the risk ratio (RR)/standard mean difference (SMD) with 95% confidence intervals (CIs) using the random-effects model. Subgroup and sensitivity analyses were used to explore the source of heterogeneity within the data. In total, 9 identified articles involving 829 patients (336 in the neoadjuvant + surgery group; 493 in the surgery group) were included in the present study, according to the criteria. The results demonstrated that there were no significant differences in blood loss (SMD=−0.11; 95% CI, −0.63–0.41; P=0.68), postoperative length of hospital stay or total length of hospital stay (SMD=0.23; 95% CI, −0.55–1.01; P=0.57) or complications (RR=1.16; 95% CI, 0.80–1.67; P=0.44) between the two groups. However, neoadjuvant therapy reduced the operation time (SMD=−0.67; 95% CI, −1.25- −0.09; P=0.02) and resulted in a greater proportion of patients choosing partial nephrectomy (RR=1.84; 95% CI, 1.47–2.31; P<0.00001). In the subgroup analysis, the blood loss was significantly lower in patients with RCC with inferior vena cava tumor thrombus in the neoadjuvant group (SMD=−1.10; 95% CI, −1.82- −0.38; P=0.003). In conclusion, the results of the present study indicated that neoadjuvant VEGF-TKI treatment in patients with RCC shortened operation time, decreased blood loss and did not cause an increase in perioperative complications. In addition, this treatment modality may encourage patients to opt for partial nephrectomy to preserve renal function.

show abstract

Section: Discussionmentioning

confidence: 99%

Effects of neoadjuvant VEGF‑TKI treatment on surgery for renal cell carcinoma: A systematic review and meta‑analysis

Zhu,

Liu,

Zhou

et al. 2024

Oncol Lett

View full text Add to dashboard Cite

show abstract

“…The most widely used immunotherapeutic drugs are PD-1/PD-L1 checkpoint inhibitors. They are antibodies against the membrane receptors PD-1 and PD-L1 and control cell migration, proliferation, and secretion of cytotoxic mediators 40 , 41 . A combination of the anti-PD-1 antibody nivolumab and the anti-CTLA-4 antibody ipilimumab has been approved for treating melanoma, RCC, CRC with high microsatellite instability, and non-small cell lung cancer 42 .…”

Section: Discussionmentioning

confidence: 99%

Comprehensive analysis of prognostic value and immune infiltration of IAPs family in hepatocellular carcinoma

Yang,

Yu,

Nie

et al. 2023

J. Cancer

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is a malignant tumor with high morbidity and mortality rates. The inhibitors of apoptosis (IAP) family act as oncogenes in various tumor types; however, their functions in HCC remain unclear. Here, we used integrated bioinformatics analysis and experimental verification to assess the expression and the prognostic and clinical value of the IAP family in HCC. Using the University of Alabama at Birmingham Cancer Data Analysis Portal (UALCAN) and the Tumor Immune Estimation Resource (TIMER), we analyzed the expression profiles of IAP family members in HCC tissue, normal tissues, and in patients with different stages and grades of HCC. We further verified the expression level of BIRC2 in 25 HCC samples and matched adjacent normal tissues using quantitative real-time PCR (qRT-PCR), and analyzed its correlation with the marker gene of T-helper type 1 cells (Th1)—STAT1. Meanwhile, the association between BIRC2 and the immunotherapeutic response or immunomodulators was confirmed using the Biomarker Exploration of Solid Tumors (BEST) database. The results showed that NAIP, BIRC2, BIRC3, XIAP, BIRC5, and BIRC6 mRNAs were overexpressed in HCC. The clinical stages, pathological grades, and other clinicopathological features of HCC were closely related to the expression levels of the IAP family members, especially the BIRC2 and BIRC5, which were found to be potential prognostic biomarkers for HCC. Expression of the IAPs was strongly associated with immune cell infiltration. Based on the infiltrative status of various immune cells, HCC patients with high BIRC2 and BIRC5 expression demonstrated poor overall survival (OS) rates. In patients with HCC, BIRC2 expression was noticeably elevated. Concurrently, the expression levels of BIRC2 and STAT1 showed a favorable correlation. BEST database analysis revealed that BIRC2 was a negative predictor of responsiveness to anti-programmed cell death ligand 1 (PD-L1)/cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) inhibitor treatment in HCC, and BIRC2 mRNA expression levels were positively correlated with the expression levels of the immune checkpoint genes programmed cell death protein 1 (PD-1), PD-L1, and CTLA-4 in HCC. Consequently, the IAP family may play a role in carcinogenesis and cancer-immune system interactions in HCC. Our results demonstrate that IAP family members may be viable predictive biomarkers and therapeutic targets for HCC.

show abstract

“…This may be due to important differences in patient population, and type and duration of therapy. 22 – 25 …”

Section: What Are the Treatment Options For Patients With Localized Rcc?mentioning

confidence: 99%

Advances in the management of renal cell carcinoma

Cardenas,

Sigurdson,

Wallis

et al. 2024

CMAJ

Self Cite

View full text Add to dashboard Cite

The emerging landscape of neo/adjuvant immunotherapy in renal cell carcinoma

Cited by 15 publications

References 80 publications

Effects of neoadjuvant VEGF‑TKI treatment on surgery for renal cell carcinoma: A systematic review and meta‑analysis

Effects of neoadjuvant VEGF‑TKI treatment on surgery for renal cell carcinoma: A systematic review and meta‑analysis

Comprehensive analysis of prognostic value and immune infiltration of IAPs family in hepatocellular carcinoma

Advances in the management of renal cell carcinoma

Contact Info

Product

Resources

About